{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:43:45Z","timestamp":1778928225852,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jiac.2019.10.006","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T01:01:34Z","timestamp":1583283694000},"page":"498-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A case of recovery from aphasia following dose reduction of cefepime by bayesian prediction-based therapeutic drug monitoring"],"prefix":"10.1016","volume":"26","author":[{"given":"Kazutaka","family":"Oda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Katanoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Iwamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayami","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Jono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.10.006_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2019.10.006_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2019.10.006_bib3","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.1954.00250020001001","article-title":"Staphylococcal infections and the problem of antibiotic-resistant staphylococci","volume":"94","author":"Spink","year":"1954","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.jiac.2019.10.006_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002184","article-title":"Will 10 million people die a year due to antimicrobial resistance by 2050?","volume":"13","author":"de Kraker","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jiac.2019.10.006_bib6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11255-015-1010-4","article-title":"Are currently GFR estimating equations and standard Kt\/V value adequate for advanced chronic kidney disease (CKD) frail elderly patients?","volume":"47","author":"Musso","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jiac.2019.10.006_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cpt1979263294","article-title":"Forecasting individual pharmacokinetics","volume":"26","author":"Sheiner","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2019.10.006_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jpba.2009.01.026","article-title":"Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: comparative pharmacokinetics in the fluid and plasma","volume":"49","author":"Ikeda","year":"2009","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jiac.2019.10.006_bib9","first-page":"302","article-title":"Adjustment of cefepime dosage in patients with renal impairment","volume":"53","author":"Yoshitsugu","year":"2005","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0028-3908(03)00188-6","article-title":"Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins","volume":"45","author":"Sugimoto","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jiac.2019.10.006_bib11","first-page":"199","article-title":"DC potentials of temporal lobe seizures in the monkey","volume":"209","author":"Mayanagi","year":"1975","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jiac.2019.10.006_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ensci.2017.08.001","article-title":"Cefepime induced neurotoxicity: a case series and review of the literature","volume":"8","author":"Isitan","year":"2017","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.jiac.2019.10.006_bib13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ndt\/gfm713","article-title":"The neurotoxicity and safety of treatment with cefepime in patients with renal failure","volume":"23","author":"Sonck","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jiac.2019.10.006_bib14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jac\/dks012","article-title":"Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports","volume":"67","author":"Durand-Maugard","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jiac.2019.10.006_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2019.10.006_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"\u03b2-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jiac.2019.10.006_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.27.2.207","article-title":"Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics","volume":"27","author":"Kessler","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jiac.2019.10.006_bib21","article-title":"Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic\/pharmacodynamic modeling","volume":"61","author":"Yadav","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.10.006_bib22","series-title":"Antimicrobial resistance: global report on surveillance","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.jiac.2019.10.006_bib23","author":"Ministry of Health, Labor and Welfare"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1930306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1930306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:59:24Z","timestamp":1761159564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X1930306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1341321X1930306X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.10.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of recovery from aphasia following dose reduction of cefepime by bayesian prediction-based therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}